Predictive ability of direct-to-consumer pharmacogenetic testing: When is lack of evidence really lack of evidence?
Pharmacogenomics , Volume 14 - Issue 4 p. 341- 344
|CYP2C19 gene, HLA DR gene, clinical practice, consumer advocacy, consumer attitude, drug efficacy, drug response, evidence based medicine, food and drug administration, gene, gene frequency, gene function, gene identification, genetic association, genetic screening, genotyping technique, human, marketing, medical research, pharmacogenetics, prediction, review, sensitivity and specificity, slco1b1 gene|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Kalf, R.R.J, Bakker, R, & Janssens, A.C.J.W. (2013). Predictive ability of direct-to-consumer pharmacogenetic testing: When is lack of evidence really lack of evidence?. Pharmacogenomics (Vol. 14, pp. 341–344). doi:10.2217/pgs.13.8